The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine.
With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), and CytoDyn Inc. (OTCQB: CYDY).
The blood-brain barrier has long been a formidable obstacle for CNS drug development. Approximately 98% of small molecules and nearly all large-molecule drugs are unable to cross the BBB, severely limiting treatment options for neurological disorders. The global burden of CNS diseases is substantial; according to the World Health Organization, neurological disorders affect hundreds of millions of people worldwide. Alzheimer’s disease alone is projected to affect over 13 million Americans by 2050, up from about 6 million today, driving an urgent need for effective therapies.
Recent breakthroughs in drug delivery technologies are beginning to change the landscape. Intranasal delivery, such as Oncotelic’s N2B system, offers a non-invasive route that bypasses the BBB by exploiting the olfactory and trigeminal nerve pathways directly into the brain. This method can achieve rapid drug onset, potentially improving outcomes for acute conditions like stroke or traumatic brain injury, as well as chronic diseases like Parkinson’s and Alzheimer’s. Other approaches under investigation include focused ultrasound to temporarily open the BBB, nanoparticles that shuttle drugs across, and engineered viral vectors for gene therapy.
The implications for the biotech market are significant. The global CNS drug delivery market was valued at over $50 billion in 2023 and is expected to grow substantially as new platforms reach commercialization. Companies that successfully develop and validate these technologies stand to capture a large share of this expanding market. Moreover, the ability to deliver existing drugs more effectively could repurpose them for CNS indications, creating new revenue streams without the cost of de novo drug discovery.
Government interest in biodefense also adds impetus. The BBB protects the brain from toxins and pathogens, but it also limits the delivery of medical countermeasures against biological threats. The U.S. Department of Defense and other agencies have invested in BBB-penetrating technologies to prepare for potential chemical or biological attacks, further driving innovation in this space.
Despite the promise, challenges remain. Scalability, safety, and regulatory hurdles must be addressed. Intranasal devices, for instance, must ensure consistent dosing and avoid mucosal irritation. However, with continued investment and research, the bottleneck of CNS drug delivery is gradually being overcome, unlocking new possibilities for treating some of the most devastating human diseases.
